Literature DB >> 20525911

Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.

James A Fagin, R Michael Tuttle, David G Pfister.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20525911      PMCID： PMC2902070          DOI： 10.1210/jc.2010-0800

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  28 in total

1.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Authors:  C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

2.  Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.

Authors:  Yong S Chang; Jalila Adnane; Pamela A Trail; Joan Levy; Arris Henderson; Dahai Xue; Elizabeth Bortolon; Marina Ichetovkin; Charles Chen; Angela McNabola; Dean Wilkie; Christopher A Carter; Ian C A Taylor; Mark Lynch; Scott Wilhelm
Journal:  Cancer Chemother Pharmacol       Date:  2006-12-08       Impact factor: 3.333

3.  Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.

Authors:  M Drosten; T Stiewe; B M Pützer
Journal:  Hum Gene Ther       Date:  2003-07-01       Impact factor: 5.695

4.  Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

Authors:  Ezra E W Cohen; Lee S Rosen; Everett E Vokes; Merrill S Kies; Arlene A Forastiere; Francis P Worden; Madeleine A Kane; Eric Sherman; Sinil Kim; Paul Bycott; Michael Tortorici; David R Shalinsky; Katherine F Liau; Roger B Cohen
Journal:  J Clin Oncol       Date:  2008-06-09       Impact factor: 44.544

5.  The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.

Authors:  Nagako Akeno-Stuart; Michelle Croyle; Jeffrey A Knauf; Roberta Malaguarnera; Donata Vitagliano; Massimo Santoro; Christine Stephan; Konstantina Grosios; Markus Wartmann; Robert Cozens; Giorgio Caravatti; Doriano Fabbro; Heidi A Lane; James A Fagin
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

6.  ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.

Authors:  Marcos Vidal; Samuel Wells; Anderson Ryan; Ross Cagan
Journal:  Cancer Res       Date:  2005-05-01       Impact factor: 12.701

7.  Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.

Authors:  F Carlomagno; M Santoro
Journal:  J Chemother       Date:  2004-11       Impact factor: 1.714

8.  Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Authors:  Bruce G Robinson; Luis Paz-Ares; Annetta Krebs; James Vasselli; Robert Haddad
Journal:  J Clin Endocrinol Metab       Date:  2010-04-06       Impact factor: 5.958

9.  Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.

Authors:  T Eisen; T Ahmad; K T Flaherty; M Gore; S Kaye; R Marais; I Gibbens; S Hackett; M James; L M Schuchter; K L Nathanson; C Xia; R Simantov; B Schwartz; M Poulin-Costello; P J O'Dwyer; M J Ratain
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

10.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Authors:  Francesca Carlomagno; Donata Vitagliano; Teresa Guida; Fortunato Ciardiello; Giampaolo Tortora; Giancarlo Vecchio; Anderson J Ryan; Gabriella Fontanini; Alfredo Fusco; Massimo Santoro
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701
View more
  6 in total

1.  The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.

Authors:  Theodore S Nowicki; Augustine L Moscatello; Edward Shin; Stimson Schantz; Raj K Tiwari; Jan Geliebter
Journal:  J Clin Endocrinol Metab       Date:  2011-08-10       Impact factor: 5.958

2.  Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.

Authors:  Theodore S Nowicki; Hong Zhao; Zbigniew Darzynkiewicz; Augustine Moscatello; Edward Shin; Stimson Schantz; Raj K Tiwari; Jan Geliebter
Journal:  Cell Cycle       Date:  2011-01-01       Impact factor: 4.534

Review 3.  Update: the status of clinical trials with kinase inhibitors in thyroid cancer.

Authors:  Samuel A Wells; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958

4.  Expression and clinical significance of STIP1 in papillary thyroid carcinoma.

Authors:  Meng-Hui Yuan; Run-Suo Zhou; Bei She; Hai-Feng Xu; Jun-Yan Wang; Long-Xiao Wei
Journal:  Tumour Biol       Date:  2013-10-27

5.  Targeted treatment of differentiated and medullary thyroid cancer.

Authors:  Shannon R Bales; Inder J Chopra
Journal:  J Thyroid Res       Date:  2011-08-02

Review 6.  The treatment landscape in thyroid cancer: a focus on cabozantinib.

Authors:  Steven P Weitzman; Maria E Cabanillas
Journal:  Cancer Manag Res       Date:  2015-08-19       Impact factor: 3.989
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.